← All indications
Melanosis
Disorders of increased melanin pigmentation that develop without preceding inflammatory disease.
Subtype terms (2)
More specific conditions that are subtypes of Melanosis in the MeSH hierarchy.
- Acanthosis Nigricans
7 drugs (5 approved, 2 experimental)
- Lentigo
11 drugs (9 approved, 2 experimental)
Drugs by status
Approved for this indication (8)
Phase 4 trials (21)
Phase 3 trials (3)
Phase 2 trials (6)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (11)
- Cairo University
- Callender Center for Clinical Research
- Howard University
- Laser and Skin Surgery Center of New York
- Sadick Research Group
- Assiut University
- University of Nice Sophia Antipolis
- Universidad Autonoma de San Luis Potosi
- Episciences, Inc.
- The University of Texas, Dallas
- Dermatology & Laser Surgery Center, Houston, TX
Organization Involved with Phase 3 Indications (11)
- Mesoestetic Pharma Group S.L.
- National Cancer Institute (NCI)
- Centro Dermatológico Dr. Ladislao de la Pascua
- Texas Tech University
- University of Chicago
- University of Indonesia
- Azidus
- Institute of Child & Mother Health, Dhaka, Bangladesh
- University of Barcelona
- American Cancer Society, Inc.
- Jinnah Postgraduate Medical Centre
Organization Involved with Phase 2 Indications (3)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (10)